Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in Argentina has shown steady growth in recent years.
Customer preferences: As in many other countries, the aging population in Argentina has led to an increase in the number of patients with cardiovascular diseases, which often require the use of anti-coagulants. Additionally, there is a growing awareness among patients and healthcare professionals about the benefits of using these drugs to prevent blood clots and strokes.
Trends in the market: One of the main trends in the Anti-Coagulants market in Argentina is the shift from traditional drugs such as warfarin to newer, more effective and safer drugs such as direct oral anticoagulants (DOACs). This trend is driven by the fact that DOACs require less monitoring and have fewer interactions with other drugs and foods, which makes them more convenient for patients and healthcare professionals.Another trend in the market is the increasing use of anti-coagulants for new indications such as the prevention of venous thromboembolism (VTE) in cancer patients. This is a significant development as cancer patients are at a higher risk of developing VTE and anti-coagulants can help prevent this complication.
Local special circumstances: One of the main challenges in the Anti-Coagulants market in Argentina is the high cost of these drugs, which limits access for many patients. This is particularly relevant for DOACs, which are generally more expensive than traditional drugs. Additionally, there is a lack of reimbursement policies for these drugs, which further limits access.
Underlying macroeconomic factors: The Argentine economy has been facing significant challenges in recent years, including high inflation, currency devaluation and political instability. These factors have had an impact on the healthcare sector, with many patients struggling to afford essential drugs such as anti-coagulants. Additionally, the pharmaceutical industry has been affected by the economic crisis, with many companies facing difficulties in importing and distributing drugs. Despite these challenges, the Anti-Coagulants market in Argentina is expected to continue growing in the coming years, driven by the increasing prevalence of cardiovascular diseases and the adoption of newer and more effective drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
